Skip to main content
Quest Diagnostics

How Predictive is Positive? Assessing PPV in cfDNA Screening for Common Trisomies

PPDC 2026 

18th Philadelphia Prenatal Diagnosis, Ultrasound/Fetal ECHO, Genetics, and Obstetrics/Maternal-Fetal Medicine Conference

Enduring Conference (until end of 2026)

Philadelphia, PA, June 4-Dec 31, 2026

Poster presentation: How Predictive is Positive? Assessing PPV in cfDNA Screening for Common Trisomies

Authors: Niemchak T, Masiello M, Glines E, Blazejewski L

Medical Specialty: Genetics, Women's Health

Related content

Audio Podcast
Discovering Prenatal Genetics
Audio Podcast
Insights into successful family planning: A diagnostics perspective
By: Damian “Pat” Alagia, III, MD, MS, MBA, FACS, FACOG
Publication
Multisite Evaluation and Validation of Optical Genome Mapping for Prenatal Genetic Testing
Test FAQ
QNatal Advanced
Test FAQ
Chromosome Analysis, POC Tissue
Test FAQ
First Trimester Screen, hCG, First Trimester Screen Hyperglycosylated hCG (h-hCG)
Test FAQ
FISH Prenatal Screen

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.